GlassScriptPhysician profile
Elmer P Ignacio
NPI 1578507604
$2,839.83
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,539 · 2020: $688 · 2021: $483 · 2022: $130.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $417.25 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $397.52 | 2019-2020 | |
| Indivior INC. | $376.84 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $358.91 | 2019-2022 | |
| Alkermes, INC. | $353.48 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $237.45 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $210.81 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $150.93 | 2019-2021 | |
| Lundbeck LLC | $146.52 | 2019-2022 | |
| Allergan, INC. | $74.65 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.64 | 2022 | |
| Avanir Pharmaceuticals, INC. | $24.93 | 2021 | |
| Eisai INC. | $19.08 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.82 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elmer Ignacio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.